Share This Post

Business Wire

Genesis Therapeutics Expands Executive Team with Addition of Will McCarthy as Chief Business Officer

Brings Extensive Biotech Experience to Drive Next Phase of Growth

BURLINGAME, Calif.–(BUSINESS WIRE)–Genesis Therapeutics, a company pioneering AI technologies to create medicines for patients with severe and unmet medical needs, today announced the appointment of Will McCarthy as chief business officer.

“We are excited to welcome Will to our rapidly growing team.” said Evan N. Feinberg, Ph.D., Genesis Therapeutics’ CEO and co-founder. “He is an industry leader with a track record of success driving strategic partnerships, commercial planning and operations at innovative biotech companies.”

Previously Mr. McCarthy was chief business officer at Generation Bio, a gene therapy company, and was part of the team that took the company public in 2020. Before that he was chief business officer at Ignyta, a company focused on genetically defined cancers, and held that role until the acquisition by Roche in 2018. Earlier in his career he was vice president of corporate development at Foundation Medicine and held business development and commercial roles at Halozyme Therapeutics, Biogen Idec and Neurocrine Biosciences. He began his career as a strategy consultant at IMS health and Deloitte Consulting and obtained a Master of Business Administration from London Business School and a Bachelor of Arts degree in economics from the University of Exeter.

Mr. McCarthy joins Genesis Therapeutics at the same time as the company was selected for the Forbes AI 50 Companies to Watch list for the second consecutive year.

“Genesis Therapeutics has already accomplished a great deal – internally and in terms of partnerships – in a very short amount of time,” commented Mr. McCarthy. “I was drawn to Genesis because of its unprecedented technology and the unique potential of its AI platform, especially in the hands of a world-class drug discovery team, to create transformative medicines for patients.”

Genesis Therapeutics completed a $52 Million Series A round of financing in December 2020 and is progressing both an internal drug pipeline, as well as select external partnerships, to create transformative therapies for patients. The company announced a multi-target partnership with Genentech in October 2020.

About the Genesis Therapeutics Molecular AI Platform

Genesis Therapeutics has developed Dynamic PotentialNet and other novel neural network algorithms that examine drug-target complexes as flexible, spatial graphs — enabling superior prediction of potency and selectivity of drug candidates. The company’s technology offers significant advantages in addressing novel, previously undruggable targets in addition to well-characterized therapeutic targets. Genesis Therapeutics’ AI engineering team partners closely with its medicinal chemists to execute and continuously strengthen an innovative process for drug discovery and early development. Genesis Therapeutics’ robust infrastructure scales the company’s AI platform on the Cloud, enabling the company to combine its proprietary Molecular Generation Engine with its field-leading molecular property predictors to search immense swaths of chemical space, approaching drug discovery as a multiparameter optimization problem.

About Genesis Therapeutics

Genesis Therapeutics is a biotechnology company that invents and deploys breakthrough AI techniques to discover and develop drugs both internally as well as in select partnerships. Genesis Therapeutics is unique in its groundbreaking deep learning technology, its synergy of machine learning with biophysical simulation and its pairing of AI with extensive biotech/pharma expertise. Genesis Therapeutics was founded in 2019 with origins in AI research at Stanford University by its co-founder and CEO, Evan Feinberg, Ph.D. The company is headquartered in Burlingame, CA. To learn more, visit genesistherapeutics.ai.

Contacts

Tara DiMilia

908-947-0500

taradimilia@tmstrat.com

Share This Post